2017
DOI: 10.21037/jtd.2017.07.28
|View full text |Cite
|
Sign up to set email alerts
|

Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
15
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 18 publications
(15 citation statements)
references
References 79 publications
(87 reference statements)
0
15
0
Order By: Relevance
“…The question why remains open and has been discussed elsewhere. 47 Low expression of EpCAM and/or CK has been suggested as possible explanations. The CellSearch yields a CTC recovery of 87-91% when cells express 1.5-2.3 × 10 6 EpCAM molecules.…”
Section: Discussionmentioning
confidence: 99%
“…The question why remains open and has been discussed elsewhere. 47 Low expression of EpCAM and/or CK has been suggested as possible explanations. The CellSearch yields a CTC recovery of 87-91% when cells express 1.5-2.3 × 10 6 EpCAM molecules.…”
Section: Discussionmentioning
confidence: 99%
“…The first evidence of the phenotypic heterogeneity is the differential expression of the EMT markers in the same CTC population. 81 Regarding genomic heterogeneity, different mutations in PIK3CAQ have been demonstrated in single breast cancer CTCs from the same patient. 82 Similarly, in lung cancer, the EGFR gene T790M mutation was found in CTCs from patients with a primary tumor negative for these mutations.…”
Section: Circulating Tumor Cellsmentioning
confidence: 99%
“…The emergence of minimally invasive liquid biopsies is also a promising approach and may provide a real-time overview of the evolving molecular landscape of the tumour, as reviewed in [24]. However, there is a huge number of potential biomarkers that have not shown significant clinical utility mainly because of lack of standardisation (different analytical techniques, different cut-off values amongst the assays, use of archival or fresh samples) and validation (sensitivity, specificity, positive and negative predictive value), as reviewed in [25,26]. Therefore, a systemic evaluation of biomarkers is necessary in the early steps of drug development in order for the most suitable ones to be included in subsequent clinical trials as surrogate end points of response and survival.…”
Section: Rapid Communicationmentioning
confidence: 99%